1-(4-Hydroxybutyl)benzotriazole | 69218-35-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: 1-(4-Hydroxybutyl)benzotriazole
• 英文别名: 4-(benzotriazol-1-yl)butan-1-ol
• CAS: 69218-35-5
• 化学式: C₁₀H₁₃N₃O
• 分子量: 191.233
• InChiKey: ZJUKGCUFFGXDAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  50.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(2,3-dihydro-1H-1,2,3-benzotriazol-1-yl)butyl acetate 在 甲醇 、 Amberlite IRC-50 H⁺ form 、 sodium methylate 作用下， 生成 1-(4-Hydroxybutyl)benzotriazole
  参考文献：
  名称：

  新型N-无环核苷的合成：苯并三唑，苯并噻嗪酮和吡ido恶嗪酮无环核苷

  摘要：

  制备了一些新颖的苯并三唑，苯并噻嗪酮和吡啶并恶嗪酮无环核苷，它们含有4-羟基丁基，4-羟基丁氧基，4-碘丁基，2-氧丙基和2,3-环氧丙氧基作为侧链。

  DOI：

  10.1002/jhet.5570330217

文献信息

• NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP1048666A1

  公开（公告）日：2000-11-02

  Novel fused tetracyclic heterocyclic compounds having a potent and highly selective effect of inhibiting cyclic GMP phosphodiesterase (cGMP-PDE) and a high safety; a process for producing the same; drugs characterized by containing at least one of these compounds as the active ingredient, in particular, preventives and/or remedies for pulmonary hypertension, ischemic heart diseases, erectile insufficiency, female sexual dysfunction or diseases against which cGMP-PDE inhibitory effects are efficacious and intermediates useful in producing the above compounds.

  新型融合四环杂环化合物，具有抑制环 GMP 磷酸二酯酶（cGMP-PDE）的强效和高选择性作用，且安全性高；其生产工艺；以含有至少一种上述化合物作为活性成分为特征的药物，特别是肺动脉高压、缺血性心脏病、勃起功能障碍、女性性功能障碍或 cGMP-PDE 抑制作用有效的疾病的预防和/或治疗药物，以及用于生产上述化合物的中间体。
• Synthesis and pharmacological evaluation of aryl/heteroaryl piperazinyl alkyl benzotriazoles as ligands for some serotonin and dopamine receptor subtypes
  作者：Alessandro Boido、Caterina Canu Boido、Fabio Sparatore

  DOI：10.1016/s0014-827x(01)01033-3

  日期：2001.4

  Thirteen [(aryl/heteroaryl-piperazinyl)alkyl]benzotriazoles were prepared as potential trazodone- and buspirone-like drugs. The synthesized compounds displayed from moderate to good affinity to the serotonin 5-HT1A receptor and only modest or poor affinity to the dopamine D-2 receptor, similar to buspirone. The introduction of substituents on the benzotriazole ring did,not improve the affinity to the 5-HT1A receptor, compared to the previously described unsubstituted derivatives. In a general pharmacological screening, which concerned only three of these compounds so far (5, 7 and 13), several in vitro and in vivo activities were observed.The guinea pig ileum contractions, induced either electrically or by several agonists, were strongly inhibited; at higher concentrations also the spontaneous tone of the guinea pig trachea was reduced. Compound 13 exhibited good analgesic activity in mice in the formalin-induced algesia and in the writhing test. The same at 30 mg kg(-1) p.o. also displayed antihypertensive activity probably related to calcium channel blockade and adrenergic alpha(1) antagonism. In binding assays, 13 showed a IC50 = 580 nM for displacing [H-3]prazosin from alpha(1) receptor.Finally, compound 5 (and, to a minor extent, compound 13) protected mice against potassium cyanide induced hypoxia. (C) 2001 Elsevier Science S.A. All rights reserved.
• US6476021B1
  申请人：——

  公开号：US6476021B1

  公开（公告）日：2002-11-05